Advertisement

Topics

Bristol-Myers Squibb and TARIS Biomedical LLC Company Profile

10:28 EST 23rd January 2019 | BioPortfolio

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new therapies for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www.tarisbiomedical.com


News Articles [936 Associated News Articles listed on BioPortfolio]

Bristol-Myers Squibb Awards “Golden Tickets” to ReviveMed and Strand Therapeutics

Bristol-Myers Squibb and LabCentral, a Cambridge, Mass.-based shared laboratory space, announced the two winners of the Bristol-Myers Squibb’s 2018 Golden Tickets for LabCentral. Due to being a plat...

Megafusion - Bristol-Myers Squibb will Celgene kaufen

Das ist ein verspäteter Silversterknaller. Bristol-Myers Squibb bietet 74 Milliarden USD für die Biotechfirma Celgene! Mit diesem Schritt könnte Bristol-Myers Squibb der führende Biopharma-Medikam...

Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration

NewsBristol-Myers Squibb and Gritstone Oncology have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy in combi...

Bristol-Myers Squibb to Acquire Celgene for $74B

Bristol-Myers Squibb (BMS) plans to acquire Celgene for approximately $74 billion, the companies said today, in a blockbuster deal designed to create a powerhouse in immunology and inflammation, cardi...

Bristol-Myers Squibb to Take Part in Citi 2018 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York. Tom Lynch, chief scientific ...

Bristol-Myers To Acquire Celgene; To Be Above 40% EPS Accretive In First Year

SUMMIT (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and Celgene Corp. (CELG) announced a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock tra...

Bristol-Myers Squibb Announces Departure of Chief Commercial Officer

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Murdo Gordon, executive vice president and chief commercial officer, is leaving the company, effective August 3...

Bristol-Myers Squibb to Acquire Celgene for $74 Billion

NEW YORK & SUMMIT, N.J.,–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger a...

Drugs and Medications [98 Associated Drugs and Medications listed on BioPortfolio]

Entecavir [Accord Healthcare Inc.]

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS . ENTECAVIR tablets, for oral use Ini...

Entecavir [Golden State Medical Supply Inc.]

ENTECAVIR TABLETS These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS . ENTECAVIR tablets...

Entecavir [AvKARE, Inc.]

Entecavir Tablets These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS. ENTECAVIR tablets,...

Entecavir [Par Pharmaceutical, Inc.]

These highlights do not include all the information needed to use Entecavir Tablets safely and effectively. See full prescribing information for Entecavir Tablets.Entecavir tablets, for oral useInitia...

Entecavir [Marlex Pharmaceuticals Inc]

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and   effectively. See full prescribing information for ENTECAVIR TABLETS.      ENTECAVIR tablets, for o...

PubMed Articles [417 Associated PubMed Articles listed on BioPortfolio]

A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients.

Belatacept (Nulojix; Bristol-Myers Squibb, New York, NY) is a biological immunosuppressive drug used for the prophylaxis of acute rejection after renal transplantation. Few studies have described bela...

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.

The unprecedented success of immuno-oncology (I-O) agents targeting the cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/programmed death-ligand 1 pathways has stimulated the rapid...

Reply to Comment on ' Role of platelet-rich fibrin on intestinal anastomosis wound healing in a rat'.

.

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers Squibb) of nivolumab (Opdivo) to submit e...

A qualitative evaluation of the appropriateness, validity, acceptability, feasibility and interpretability of the Bristol Impact of Hypermobility (BIoH) questionnaire.

The Bristol Impact of Hypermobility (BIoH) questionnaire is a condition-specific patient-reported outcome measure developed for adults with Joint Hypermobility Syndrome (JHS). It has previously demons...

Clinical Trials [187 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Safety and Tolerability Study of the Taris Placebo System

The aim of this protocol is to evaluate the tolerability of the Taris placebo system for the development program and to provide key safety and tolerability data for the Taris platform.

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Companies [727 Associated Companies listed on BioPortfolio]

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

Bristol-Myers Squibb and TARIS Biomedical LLC

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new therapies for millions of patients suffering from difficult-to-treat ...

More Information about "Bristol-Myers Squibb and TARIS Biomedical LLC" on BioPortfolio

We have published hundreds of Bristol-Myers Squibb and TARIS Biomedical LLC news stories on BioPortfolio along with dozens of Bristol-Myers Squibb and TARIS Biomedical LLC Clinical Trials and PubMed Articles about Bristol-Myers Squibb and TARIS Biomedical LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bristol-Myers Squibb and TARIS Biomedical LLC Companies in our database. You can also find out about relevant Bristol-Myers Squibb and TARIS Biomedical LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

Bladder Cancer
Non-invasive bladder cancer is a cancer that is only in the inner lining of the bladder. Invasive bladder cancer is cancer that has spread into the deeper walls of the bladder. When the cancer has spread outside the bladder to other parts of the body, th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record